DelMar Pharmaceuticals to Present Clinical and Preclinical Abstracts for VAL-083 at the American Association of Cancer Research (AACR) Annual Meeting in April 2015

- Updated Phase I/II clinical trial data on the maximum tolerated dose for VAL-083 in the treatment of glioblastoma multiforme (GBM) to be presented -

- Preclinical VAL-083 data demonstrate potential to treat non-small cell lung cancer (NSCLC) and temozolomide-resistant GBM -

VANCOUVER, British Columbia and MENLO PARK, Calif., Feb. 24, 2015 /PRNewswire/ - DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (“DelMar” and the “Company”), today announced that it will be presenting three abstracts based on clinical and preclinical research with its lead product candidate VAL-083 (dianhydrogalactitol) at the 106th Annual Meeting of the American Association for Cancer Research (AACR), being held April 18-22, 2015, in Philadelphia, Pennsylvania.

The Company’s clinical abstract number 1201, entitled, "Phase I/II study of dihydrogalactitol in patients with recurrent malignant glioma" has been accepted for presentation at AACR. The date and time of DelMar’s VAL-083 data presentation will be announced by the meeting’s program committee prior to the conference. DelMar is conducting a Phase I/II clinical study with VAL-083 to determine the maximum tolerated dose (MTD) using an optimized dosing scheme in preparation for advancing VAL-083 into registration trials as a potential new therapy for the treatment of refractory glioblastoma multiforme (GBM), the most common and deadly form of human brain cancer.

Additionally, DelMar will present abstract number 751, entitled, "In vitro activity of dihydrogalactitol alone or with platinum drugs in the treatment of non-small cell lung cancer," during the AACR Therapeutic Resistance in Lung Cancer session on Sunday, April 19, 2015, from 1:00 p.m. - 5:00 p.m Eastern Time. VAL-083 has previously demonstrated activity against non-small cell lung cancer (NSCLC) in preclinical and clinical trials, and is approved for treatment of lung cancer in China, suggesting that it may be a therapeutic option for drug-resistant NSCLC. This in vitro study was designed to investigate the role of p53 status in the activity of VAL-083; VAL-083 activity in comparison
to cisplatin and oxaliplatin; and the combination of VAL-083 with cisplatin or oxaliplatin.

The Company's preclinical abstract entitled, "Dianhydrogalactitol inhibits the growth of glioma stem and non-stem cultures, including temozolomide-resistant cell lines, in vitro and in vivo," (abstract number 2562) will be presented on Monday, April 20, 2015, between 1:00 p.m. - 5:00 p.m. Eastern Time during the AACR session on DNA Damaging and Antimitotic Agents and Cytotoxicity Modulators. The standard of care for GBM patients is surgical resection followed by temozolomide (TMZ) and irradiation (XRT), but TMZ-resistance has emerged as a significant unmet medical need. This study's objective was to investigate how cancer stem cells and non-cancer stem cells respond to VAL-083 alone or in combination with XRT. The study further investigated the activity of VAL-083 in in vivo models of drug-resistant GBM in comparison to TMZ.

About VAL-083
VAL-083 is a first-in-class, small-molecule chemotherapeutic with a unique mechanism of action. In more than 40 Phase 1 and 2 clinical studies sponsored by the National Cancer Institute, VAL-083 has shown safety and efficacy in treating a number of cancers including lung, brain, cervical, ovarian tumors and leukemia. VAL-083 is approved in China for the treatment of chronic myelogenous leukemia and lung cancer and has received orphan drug designation in Europe and the U.S. for the treatment of gliomas. As a potential treatment for glioblastoma, VAL-083's mechanism of action is unaffected by the expression of MGMT, a DNA repair enzyme that causes chemotherapy resistance to front-line treatment with Temodar® (temozolomide). DelMar is currently studying VAL-083 in a Phase 1/2 clinical trial for patients with refractory glioblastoma multiforme.

About DelMar Pharmaceuticals, Inc.
DelMar Pharmaceuticals, Inc. was founded to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.

For further information, please visit www.delmarpharma.com; or contact Jeffrey A. Bacha, President & CEO (604) 629-5989 or Amato & Partners LLC, Investor Relations admin@amatoandpartners.com follow us on Twitter @delmarpharma or Facebook.com/delmarpharma.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to
develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.


SOURCE DelMar Pharmaceuticals, Inc.